Drug Profile
BRL 54912
Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Thrombolytics
- Mechanism of Action Fibrinogen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 29 May 1995 New profile
- 29 May 1995 Discontinued-Preclinical for Thrombosis in United Kingdom (Unknown route)